Latanoprost

CAS 130209-82-4 17 current records 5 historicalSmall Molecule

Who holds supplier records for Latanoprost? 17 organisations hold a current record for Latanoprost: an active US FDA Type II Drug Master File or a CEP. A further 5 organisations have only historical (inactive) DMF filings. 14 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: United States (2), Taiwan (2), Italy (2), India (2) and 8 other countries (8); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Latanoprost: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/latanoprost

Reading the evidence

  • 17 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Latanoprost expires 8 Jul 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (17)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Latanoprost. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Latanoprost sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (14)

Certificates of Suitability on the EDQM register for Latanoprost, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 15 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
EVERLIGHT CHEMICAL INDUSTRIAL CORP. TaipeiTW
CEP 2021-002 - Rev 01
Latanoprost
Jul 2026—
FDC LIMITED MumbaiIN
CEP 2024-162 - Rev 02
Latanoprost
May 2026—
MSN LABORATORIES PRIVATE LIMITED SangareddyIN
CEP 2023-113 - Rev 01
Latanoprost
May 2026Inspected Aug 2026
Slovakia
CAYMAN PHARMA S.R.O. NeratoviceCZ
CEP 2023-147 - Rev 01
Latanoprost
Sept 2025Inspected May 2026
Czechia
C-SQUARED PHARMA LIMITED CorkIE
CEP 2024-091 - Rev 00
Latanoprost
Sept 2025—
CAYMAN CHEMICAL COMPANY, INC. Ann ArborUS
CEP 2022-093 - Rev 01
Latanoprost
Nov 2024—
CHIROGATE INTERNATIONAL INC. Taoyuan CityTW
CEP 2021-379 - Rev 01
Latanoprost
Aug 2024—
KYOWA PHARMA CHEMICAL CO., LTD. TakaokaJP
CEP 2022-107 - Rev 01
Latanoprost
Jan 2024Inspected Dec 2024
Japan
YS LIFE SCIENCE Co. Ltd. Hwaseong-siKR
CEP 2021-058 - Rev 01
Latanoprost
Dec 2023—
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2022-174 - Rev 00
Latanoprost
Oct 2023Inspected Jan 2024
Hungary
GENTEC, S.A. L´Hospitalet de LlobregatES
R0-CEP 2021-059 - Rev 00
Latanoprost
Jul 2023—
NEWCHEM S.p.A. MilanoIT
R0-CEP 2020-368 - Rev 02
Latanoprost
Jul 2023—
INDUSTRIALE CHIMICA S.R.L. SaronnoIT
R0-CEP 2022-071 - Rev 00
Latanoprost
Mar 2023—
EUROAPI HUNGARY Ltd. BudapestHU
R0-CEP 2021-352 - Rev 00
Latanoprost
Dec 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (5)

Organisations whose Type II DMFs for Latanoprost are no longer active. These show a past filing, not current supply.

Show all 5 historical records
  • India · Inactive DMF 27645 · filed Dec 2013
  • PATHEON API MANUFACTURING INC
    Inactive DMF 25924 · filed Mar 2012
  • MYLAN LABORATORIES LTD
    Inactive DMF 24208 · filed Sept 2010
  • Sai Life Sciences Limited
    India · Inactive DMF 20925 · filed Oct 2007
  • RESOLUTION CHEMICALS LTD
    Inactive DMF 15462 · filed May 2001

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (9 listed products contain Latanoprost). The latest listed patent expires 8 Jul 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Latanoprost is a prostaglandin F2α analog used as an ophthalmic solution to lower intraocular pressure in glaucoma patients. It works by increasing the outflow of aqueous fluid from the eyes.

Chemical identity

IUPAC name
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
Canonical SMILES
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O
InChIKey
GGXICVAJURFBLW-CEYXHVGTSA-N
Synonyms
Xalatan API, iyuzeh, latanoprost (isopropyl ester), phxa-41, phxa41, rocklatan component latanoprost, t-2345, t2345, xa-41, xa41, xalacom component latanoprost, xalatan

Therapeutic areas

OphthalmologyGlaucoma

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Latanoprost?

17 organisations hold an active US FDA Type II Drug Master File or a CEP for Latanoprost: Cayman Chemical Company (United States), CAYMAN PHARMA SRO (Czechia), CHIROGATE INTERNATIONAL INC (Taiwan), EUROAPI HUNGARY LTD (Hungary), EVERLIGHT CHEMICAL INDUSTRIAL CORP (Taiwan), INDUSTRIALE CHIMICA SRL (Italy), KYOWA PHARMA CHEMICAL CO LTD (Japan) and MSN Laboratories Private Limited (India), and 9 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Latanoprost Drug Master Files are active?

Cayman Chemical Company (DMF 17445), CAYMAN PHARMA SRO (DMF 26081), CHIROGATE INTERNATIONAL INC (DMF 18343), EUROAPI HUNGARY LTD (DMF 26728), EVERLIGHT CHEMICAL INDUSTRIAL CORP (DMF 21504), INDUSTRIALE CHIMICA SRL (DMF 25931), KYOWA PHARMA CHEMICAL CO LTD (DMF 32989) and MSN Laboratories Private Limited (DMF 27307) and 9 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Latanoprost records mean?

5 organisations have only inactive Type II DMFs for Latanoprost. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Latanoprost have a European Certificate of Suitability?

Yes. 14 organisations hold a valid CEP for Latanoprost on the EDQM register, including EVERLIGHT CHEMICAL INDUSTRIAL CORP. Taipei (TW), FDC LIMITED Mumbai (IN), MSN LABORATORIES PRIVATE LIMITED Sangareddy (IN), CAYMAN PHARMA S.R.O. Neratovice (CZ), C-SQUARED PHARMA LIMITED Cork (IE) and CAYMAN CHEMICAL COMPANY, INC. Ann Arbor (US) and 8 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Latanoprost?

Yes. The latest patent listed for an approved US product containing Latanoprost expires 8 Jul 2031, across 9 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Latanoprost supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Latanoprost?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.